

ONCODAILY MEDICAL JOURNAL

abstract

Survival and prognostic factors of patients with medulloblastoma of the WNT molecular group

Zheludkova Olga

DOI: 10.69690/ODMJ-018-0425-1823



SIOP Asia, 2025, Saudi Arabia

abstract



Survival and prognostic factors of patients with medulloblastoma of the WNT molecular group

Author: Zheludkova Olga

Affiliation: Scientific and Practical Center for Specialized Medical Care for Children named after V.F. Voyno-Yasenetsky Moscow, 38 Aviatorov St., Moscow, 119620, Russia

DOI: [10.69690/ODMJ-018-0425-1823](https://doi.org/10.69690/ODMJ-018-0425-1823)

Introduction: Medulloblastoma of the WNT molecular group (MB-WNT) accounts for 10% of medulloblastomas and is characterized by a favorable prognosis. Reduction of therapy intensity for prognostically favorable MB-WNT seems justified.

Methodology: In the period from 1993 to 2021, the analysis included 85 patients with WNT MB under the age of 18 years, who after tumor removal received of craniospinal irradiation (CSI) with a boost to the PF and parallel chemotherapy, as well as 6-8 cycles of polychemotherapy according to the HIT MED protocol.

Results: The median age at diagnosis was 10 years (min 3, max 17). All patients had the classic variant of MB. Metastases were detected in 18 patients (21.2%), residual tumor was detected in 32 patients (37.7%). Stage M1 was detected in 6 patients (7.05%), stage M2 in 2 (2.35%), stage M3 in 10 (11.8%). Somatic mutations in the TP53 gene were detected in 10 patients (7.1%). Patients were distributed by risk groups: low – 58.8%, standard – 15.3%, high – 25.9%. At the time of analysis, 74

patients (87.1%) alive, 11 patients (12.9%) died, relapse was diagnosed in 6 patients (7.1%), of whom 5 died from disease progression, 1 patient is alive in the second remission. The 10-year PFS was 0.92.

The overall 10-year OS was 0.86. The median overall survival was 112 months. PFS was statistically higher in female patients compared to male patients: 0.98 and 0.81, respectively, $p=0.02036$; at M0 stage compared to M+ stage, 0.97 and 0.74 ($p=0.00437$); with total tumor resection compared with residual tumor, 0.96 and 0.85 ($p=0.03090$); in low-risk compared to standard and high risk groups – 0.98, 0.92 and 0.78, respectively ($p=0.03579$); in the absence of somatic mutation in the TP53 gene compared to cases of mutation detection in tumor, respectively 0.98 and 0.50 ($p=0.00000$). In a multivariate analysis, PFS was influenced by the stage of the disease and the presence of a somatic mutation in the TP53 gene in the tumor.

Conclusion: Prognostic factors for MB WNT were gender, M stage, resection volume, risk group, somatic mutation TP53.